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Value for Money? Array Genomic Hybridization
for Diagnostic Testing for Genetic Causes
of Intellectual Disability
Dean A. Regier,1,2,* Jan M. Friedman,3 and Carlo A. Marra4
Array genomic hybridization (AGH) provides a higher detection rate than does conventional cytogenetic testing when searching for
chromosomal imbalance causing intellectual disability (ID). AGH is more costly than conventional cytogenetic testing, and it remains
unclear whether AGH provides good value for money. Decision analytic modeling was used to evaluate the trade-off between costs, clin-
ical effectiveness, and beneﬁt of an AGH testing strategy compared to a conventional testing strategy. The trade-off between cost and
effectiveness was expressed via the incremental cost-effectiveness ratio. Probabilistic sensitivity analysis was performed via Monte Carlo
simulation. The baseline AGH testing strategy led to an average cost increase of $217 (95% CI $172–$261) per patient and an additional
8.2 diagnoses in every 100 tested (0.082; 95% CI 0.044–0.119). The mean incremental cost per additional diagnosis was $2646 (95% CI
$1619–$5296). Probabilistic sensitivity analysis demonstrated that there was a 95% probability that AGH would be cost effective if deci-
sion makers were willing to pay $4550 for an additional diagnosis. Our model suggests that using AGH instead of conventional karyo-
typing for most ID patients provides good value for money. Deterministic sensitivity analysis found that employing AGH after ﬁrst-line
cytogenetic testing had proven uninformative did not provide good value for money when compared to using AGH as ﬁrst-line testing.Intellectual disability (ID) is a life-long condition that has
signiﬁcant impact on the affected person and his or her
family.1–3 Clinical geneticists seek to establish the cause of
a child’s disability to provide accurate genetic counseling,
prognosis, and management. A chromosomal abnormality
is the most commonly recognized cause of ID,4,5 and cyto-
genetic analysis is the standard clinical approach to identi-
fying chromosomal abnormalities. Conventional cytoge-
netic analysis employs a karyotype to assay the entire
genome (some 6000 million base pairs [6000 Mb] of DNA
in a single test) but cannot detect chromosomal rearrange-
ments smaller than 5–10 Mb. Fluorescence in situ hybrid-
ization (FISH) and subtelomeric FISH have much better
resolution, but these approaches provide information on
just one or a few speciﬁc locations in the genome.
Array genomic hybridization (AGH) can identify submi-
croscopic chromosomal imbalance 100 or more times
smaller than that detectable by standard cytogenetic anal-
ysis anywhere in the genome. Recent studies suggest that
AGH can detect a causal chromosomal abnormality in
twice as many patients as karyotyping.6,7 As a result,
many laboratories are now offering AGH as a clinical test,
and some clinical geneticists advocate the use of AGH
instead of conventional cytogenetic analysis for evaluating
children with ID.8–10
The cost of AGH, however, is substantially more than
that of conventional cytogenetic analysis, and there is
limited evidence on whether a diagnostic testing strategy
that includes AGH will provide good value for money.11
This report examines the cost-beneﬁt of a testing strategy
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a conventional cytogenetic testing strategy to identify
chromosomal imbalance causing ID.
A decision analytic model (Figure 1) was used to synthe-
size the economic and clinical outcomes accrued to a hypo-
thetical cohort of individuals with idiopathic ID under-
going a conventional or AGH testing strategy. The time
horizon of the model was 1 year. In the AGH testing
pathway, children who were not suspected of having
a trisomy had AGH testing as ﬁrst-line. For those children
with suspected trisomy 21 (MIM #190865), trisomy 18, or
trisomy 13, a karyotype was used as ﬁrst line, followed by
AGH if a diagnosis was not established. Trisomy 21, 18,
or 13 were included in the economic model because AGH
can be applied to these patients if karyotyping does not
establish a diagnosis. If an imbalance was detected by AGH,
targeted FISH (in the parents and child) and karyotyping
(in the child) was used to conﬁrm the ﬁnding.
The ﬁrst-line genetic test in the conventional testing
pathway was karyotyping; the probability of receiving
a genetic diagnosis with a karyotype differed between
those with and without suspected trisomy 21, 18, or 13.
If a karyotype did not provide a diagnosis, it was assumed
that testing with either targeted FISH (via single or
multiple probes) or subtelomeric FISH was conducted.
Identiﬁed chromosomal abnormalities of unknown clin-
ical relevance after FISH were assumed to require targeted
FISH testing of both parents to establish whether the chro-
mosomal abnormality occurred de novo.
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Figure 1. Decision Analytic Model
Legend: open square, decision node; open
circle, transition probability; left open
triangle, terminal node; Dx, diagnosis;
outcome, cost; effectiveness.strategies.12 Mean cost and cost differences (DC) were
examined from the perspective of the British Columbia
Ministry of Health Services. The Ministry of Health insures
residents of British Columbia for medically required
services provided by clinicians and other health care prac-
titioners, including laboratory services and diagnostic
procedures. Consequences include the clinical or personal
utility associated with a strategy.13 In this analysis, conse-
quences were measured via (1) incremental effectiveness
(DE), which represented clinical utility and was calculated
as the number of additional diagnoses provided by AGH;
and (2) incremental beneﬁt (DWTP), which is a metric
that combines clinical and personal utility with prefer-
ences from a discrete choice experiment (DCE).14 Exam-
ining issues surrounding value for money implies that
a trade-off may exist between increased effectiveness and
cost. The metrics used to investigate value for money
were the incremental cost-effectiveness ratio (ICER; DC/
DE) and the net beneﬁt of AGH versus conventional testing
(DWTP-DC).
The transition probabilities populating the decision
model were informed through published literature or chart
review. The proportion of children having a karyotype for
suspected trisomy 21, 18, or 13 and the probability of
receiving a genetic diagnosis for these individuals were
taken from a study by Rauch et al.4 The probability of es-
tablishing a diagnosis with a karyotype in those without
trisomy 21, 18, or 13 came from van Karnebeek et al.15
The probability of undergoing targeted or subtelomeric
FISH testing after receiving no causal genetic diagnosis
with karyotyping was estimated through chart review.
The chart review utilized medical records maintained at
the Provincial Medical Genetics Programme at Children’s
& Women’s Hospital in Vancouver, Canada. For inclusion
in the review, individuals were required to be between the
ages of 5 and 10 years, have moderate to severe ID, and
live in metro Vancouver. Moderate to severe ID was
deﬁned as being at least four standard deviations below
the mean on standardized developmental tests recorded766 The American Journal of Human Genetics 86, 765–772, May 14, 2010in the chart. Eligible families of chil-
dren with ID were contacted via
mail; informed consent to use the
data was obtained from 162 families.
Ethics approval for the chart review
was granted by the Behavioral
Research Ethics Board, University of
British Columbia.
The conditional probability of
receiving a diagnosis with targeted
FISH subsequent to karyotyping wasinformed with a substudy by Rauch et al.,4 and the condi-
tional probability of receiving a diagnosis with subtelo-
meric FISH was obtained from a retrospective study of
individuals who had such testing after cytogenetic analysis
had failed to provide a diagnosis.16
The AGH testing pathway requires the number of
genetic diagnoses provided by AGH after karyotyping
and when AGH is used as ﬁrst-line testing. For the former,
the probability of diagnosis was obtained by pooling data
from several published reports examining AGH for idio-
pathic ID.17–26 The number of genetic diagnoses obtained
when AGH is used as a ﬁrst-line test is difﬁcult to establish
because published studies use AGH for patients who have
undergone clinical evaluation and initial cytogenetic
testing. We assumed that AGH would identify each of
the diagnoses obtained by karyotyping. This probability
was then added to the conditional estimate of obtaining
a diagnosis with AGH.
In the cost analysis, resource utilization associated with
laboratory testing (excluding cytogenetic, FISH, or array
testing) and individual clinical assessments was informed
through the chart review. The chart review included the
utilization of other laboratory tests; visits to general practi-
tioners, pediatricians, and other specialists; and individual
developmental assessments (e.g., for autism, delayed
development of speech, etc.). The resource utilization of
each case was subsequently divided into the laboratory
or clinical assessments before initial cytogenetic analysis,
and laboratory or clinical assessment after initial cytoge-
netic analysis if a diagnosis was or was not obtained.
Unit costs attached to resource utilization and for cytoge-
netic and FISH testing were obtained from the Medical
Services Plan (MSP) fee schedule available from the
Ministry of Health. The MSP fee schedule lists the actual
reimbursements that the Ministry of Health pays for
health services that are insured. The cost for AGH testing
was obtained from the Cytogenetics Laboratory at the
British Columbia Children’s Hospital because AGH is not
currently covered in the MSP fee schedule; the fee used
in the model is the reimbursement paid by the insurer. All
costs are reported in 2007 Canadian dollars.
Combining the clinical and personal utility of genetic
testing was achieved by using the willingness to pay
(WTP) for a gain in the probability of obtaining a causal
genetic diagnosis for ID, which was valued via data from
families of children with ID as reported by Regier et al.11
The present study uses the econometric results of Regier
et al.,11 but our estimate of WTP will differ because the
number of additional genetic diagnoses is predicted by
the decision analytic model (Regier et al.11 assume a rate
of diagnosis). To calculate beneﬁt, we generated aWTP esti-
mate for each testing pathway with the multiple alterna-
tives approach.11
The decision analytic model was programmed via Tree-
Age Pro (TreeAge Pro Inc, Williamstown, MA, USA). A
number of deterministic sensitivity analyses informing
the uncertainty surrounding key assumptions were under-
taken. (1) Multiplex ligation-dependent probe ampliﬁca-
tion (MLPA) is an inexpensive alternative to subtelomeric
FISH. A sensitivity analysis was conducted to include
MLPA instead of subtelomeric FISH in the conventional
testing strategy; we assumed that the approaches would
have identical rates of diagnosis, but the cost of MLPA
was $40. (2) Cytogenetic laboratories can employ a strategy
where AGH is used after a normal karyotype for children
without suspected trisomy 21, 18, or 13. The cost-beneﬁt
of this strategy was examined against (i) the conventional
testing strategy deﬁned in the baseline analysis; and (ii) the
AGH testing strategy deﬁned in the baseline analysis. (3)
The ﬁnal sensitivity analysis examined the cost-beneﬁt of
an AGH testing strategy versus a conventional strategy
solely for those individuals without suspected trisomy
21, 18, or 13.
Probabilistic sensitivity analysis was conducted to
account for the joint sampling uncertainty of the parame-
ters in the decision model. Probabilistic sensitivity analysis
requires assigning distributions to each uncertain param-
eter. The beta distribution was speciﬁed for the probability
of obtaining a diagnosis and for the probability of transi-
tioning to subsequent genetic testing.27 The cost associ-
ated with laboratory testing was assumed to follow the
gamma distribution.28 Uncertainty was propagated
throughout the decision analytic model via Monte Carlo
simulation with 10,000 draws taken from the input distri-
butions. The decision uncertainty surrounding the adop-
tion of an AGH testing strategy was examined with the
cost-effectiveness acceptability curve (CEAC). The CEAC
plots the probability that an AGH strategy will be cost
effective at a given threshold of WTP that decision makers
may have for an effectiveness gain, which is denoted as l.
In the context of this analysis, l represents decision
makers’ WTP for an additional genetic diagnosis. For
each analysis we report the l that suggests there is a 95%
probability that an AGH strategy will be cost effective.
The results of the decision model for each transition
probability are presented in Table 1. In the conventionalThe Ametesting strategy, the mean probability that karyotyping
establishes a diagnosis was 0.161 (95% conﬁdence interval
[CI] 0.127–0.196); 0.161 is the sum of 0.095 (0.1283 0.741
in Table 1) for trisomy cases and 0.065 (0.872 3 0.075 in
Table 1) for nontrisomy cases. The conditional probability
of receiving a diagnosis with either subtelomeric or tar-
geted FISH testing after failing to receive a diagnosis
with an initial karyotype was 0.032 (95% CI 0.024–
0.043). The overall probability of establishing a diagnosis
in the conventional testing pathway was 0.192 (95% CI
0.159–0.228).
In the AGH testing strategy, 0.099 (95% CI 0.077–0.123)
diagnoses would be established via karyotyping or AGH (if
the karyotype was negative) for individuals who were
suspected of having trisomy 21, 18, or 13. For nontrisomy
cases, the probability of establishing a diagnosis when
AGH was used as ﬁrst-line was 0.18 (95% CI 0.157–
0.205); 0.18 is from 0.872 3 0.202 in Table 1. The proba-
bility of establishing a causal diagnosis in the AGH testing
pathway was 0.275 (95% CI 0.245–0.306).
Table 1 also presents the cost of laboratory investigations
and other clinical visits or developmental tests estimated in
the model. The mean per patient cost of genetic testing for
ID in the conventional testing pathway was $572 (95% CI
$553–$592); when all other costs for laboratory and indi-
vidual assessments were included, the mean was $2763
(95% CI $2499–$3052). In the AGH testing pathway, the
average per patient cost of genetic testing for ID alone was
$829 (95% CI $805–$855), and the total per patient cost
of all testing was $2980 (95% CI $2727–$3254).
Table 2 summarizes the mean costs, effects, and beneﬁts
of each strategy. The incremental cost of AGH including
genetic testing and other laboratory and clinical assess-
ments was $217 (95% CI $172–$261) more for the AGH
strategy. The incremental probability of obtaining a diag-
nosis provided by undertaking an AGH strategy (DE) was
0.082 (95% CI 0.044–0.119): the model predicts that an
additional 8.2 children in 100 tested will receive a causal
diagnosis.
AGH is incrementally more costly and more effective,
and decision makers will need to make a judgment
regarding whether the additional diagnoses provided by
the AGH strategy warrant the additional costs. The ICER
characterizes the value for money trade-off. The ICER
was $2646 (95% CI $1619–$5296) when all costs were
included in the analysis. This suggests that the health
care payer will have to spend $2646 (95% CI $1619–
$5296) per additional diagnosis. We do not know decision
makers’ WTP for an additional diagnosis (l) and we
cannot say how the statistical uncertainty affects the value
for money trade-off. For the latter, the CEAC gives the
exact probability that an AGH testing strategy will be
cost effective at different thresholds of l (Figure 2). AGH
will reach a 95% probability of being cost effective when
l ¼ $4550.
By using the preferences of parents who have a child
with ID, we estimated that WTP was $1053 (95% CIrican Journal of Human Genetics 86, 765–772, May 14, 2010 767
Table 1. Transition Probabilities in the Decision Model
Parameter Mean (Standard Error) 95% CI Reference Number
Probability of Receiving First Line Genetic Test
Karyotype for trisomy 21, 13, or 18 0.128 (0.013) 0.103–0.157 4
Karyotype (conventional testing strategy)/GH (AGH testing strategy) 0.872 (0.014) 0.845–0.898 4
Conditional Probability after Karyotype and Not Receiving a Diagnosis (Conventional Testing Strategy)
Targeted FISH 0.561 (0.04) 0.485–0.637 chart review
Subtelomeric FISH 0.439 (0.04) 0.365–0.516 chart review
Probability of Receiving a Genetic Diagnosis
Karyotype for suspected syndrome (trisomy 21; trisomy 13; trisomy 18) 0.741 (0.05) 0.634–0.835 4
Karyotype 0.075 (0.016) 0.046–0.109 15
Subtelomeric FISH 0.026 (0.002) 0.023–0.029 16
Targeted FISH 0.047 (0.006) 0.031–0.066 4
AGH (ﬁrst line test) 0.202 (0.018) 0.178–0.229 assumption
AGH (second line test) 0.126 (0.013) 0.101–0.153 17–26
Cost of Genetic Testing
Karyotype $280 N/A MSP
FISH (single probe) $187 N/A MSP
Targeted FISHa $221 (9.8) $202–$240 MSP
Subtelomeric FISH $444 N/A MSP
AGH $710 N/A current cost
Cost of Laboratory Testingb
Before cytogenetic testing $1054 (66) $928–$1191 chart review
After ﬁrst cytogenetic test with diagnosis $742 (143) $489–$1042 chart review
After ﬁrst cytogenetic test without diagnosis $1227 (144) $951–$1528 chart review
Abbreviations: CI, confidence interval; FISH, fluorescent in situ hybridization; MSP, Medical Services Plan; N/A, not applicable as these costs are charged to the
British Columbia Ministry of Health and there is no variance in payment. All costs are in 2007/2008 Canadian dollars.
a These costs and CIs are derived from the percentage of individuals having a test after karyotyping as identified by the chart review: 45% had 1 targeted FISH,
5.6% had 2 targeted FISH, 1.4% had 3 targeted FISH.
b Does not include the cost of cytogenetic analysis.$432–$1828) for an additional 8.2 diagnoses for every
100 children who are tested. For comparability with the
ICER, the WTP for an increase in the rate of diagnosis
can be converted into the WTP per additional diagnosis
by dividing the WTP result by the increased probability
of diagnosis. The WTP per diagnosis was calculated as
$12,792 (95% CI $6,508–$19,207). The CEAC (Figure 2)
shows that there is more than a 99% probability that the
AGH testing strategy is cost effective at this threshold of
WTP. The net beneﬁt statistic also suggested that AGH
was cost beneﬁcial (Table 2). Given an incremental cost
of $217 (95% CI $172–$261), the expected net beneﬁt
per child tested was $836 (95% CI $203–$1616), which is
signiﬁcantly different from no difference in net beneﬁt.
The results of the sensitivity analyses are presented in
Table 2. Sensitivity analysis 1 examined using MLPA
instead of subtelomeric FISH. The mean cost in the
conventional strategy was $2615 (95% CI $2351–$2903).768 The American Journal of Human Genetics 86, 765–772, May 14,The ICER was $4463 (95% CI $2962–$8446) and there
was a 95% probability that AGH is cost effective when
l ¼ $7500. The net beneﬁt using parents’ WTP for an addi-
tional 8.2 diagnoses was $687 (95% CI $58–$1464), which
suggests that the AGH strategy remains an attractive
option when MLPA is used.
Sensitivity analysis 2 (i) examined the scenario where
AGH is employed subsequent to initial karyotyping versus
conventional cytogenetic testing. This AGH strategy had
an average cost of $3090 (95% CI $2837–$3367) and an
incremental effectiveness of 0.074 (95% CI 0.051–0.099)
when compared to the conventional strategy in the base-
line analysis. The ICER was $4418 (95% CI $3226–
$6432) and there was a 95% probability AGH is cost effec-
tive when l ¼ $6000. Using parents’ WTP, the beneﬁt was
$948 (95% CI $445–$1563) and the net beneﬁt was $621
(95% CI $114–$1234). Sensitivity analysis 2 (ii) examined
AGH after karyotyping against the AGH strategy deﬁned in2010
Table 2. Cost-Effectiveness Results and Sensitivity Analyses
Baseline Analysis
Mean AGH Strategy (95% CI) Mean Conventional Strategy (95% CI) Mean Difference (95% CI)
Cost $2980 ($2727–$3254) $2763 ($2499–$3052) $217 ($172–$261)
Effectiveness 0.275 (0.245–0.306) 0.192 (0.159–0.228) 0.082 (0.044–0.119)
ICER $2646 ($1619–$5296)
Beneﬁt $1053 ($432–$1828)
Net beneﬁt $836 ($203–$1616)
Sensitivity Analysis 1
Mean AGH Strategy (95% CI) Mean Conventional Strategy (95% CI) Mean Difference (95% CI)
Cost $2980 ($2727–$3254) $2615 ($2351–$2903) $366 ($322–$409)
Effectiveness 0.275 (0.245–0.228) 0.192 (0.159–0.228) 0.082 (0.049–0.142)
ICER $4463 ($2962–$8446)
Beneﬁt $1053 ($432–$2828)
Net beneﬁt $687 ($58–$1464)
Sensitivity Analysis 2 (i)
Mean Karyotype/AGH Strategy (95% CI) Mean Conventional Strategy (95% CI) Mean Difference (95% CI)
Cost $3090 ($2837–$3367) $2763 ($2499–$3052) $327 ($291–$365)
Effectiveness 0.267 (0.230–0.304) 0.192 (0.159–0.228) 0.074 (0.051–0.099)
ICER $4418 ($3226–$6432)
Beneﬁt $948 ($445–$1563)
Net beneﬁt $621 ($114–$1234)
Sensitivity Analysis 2 (ii)
Mean Karyotype/AGH Strategy (95% CI) Mean AGH Strategy (95% CI) Mean Difference (95% CI)
Cost $3090 ($2837–$3367) $2980 ($2727–$3254) $110 ($73–$143)
Effectiveness 0.267 (0.23–0.304) 0.275 (0.245–0.228) 0.008 (0.030–0.0189)
ICER $13,750 weak dominance
Net beneﬁt 214 ($567–$169)
Sensitivity Analysis 3
Mean AGH Strategy (95% CI) Mean Conventional Strategy (95% CI) Mean Difference (95% CI)
Cost $3065 ($2801–$3350) $2832 ($2554–$3138) $233 ($183–$281)
Effectiveness 0.201 (0.176–0.229) 0.110 (0.081–0.145) 0.091 (0.048–0.132)
ICER $2766 ($1543–$5267)
Beneﬁt $1117 ($423–$1984)
Net beneﬁt $884 ($179–$1757)
Abbreviations: ICER, incremental cost-effectiveness ratio; CI, confidence interval; benefit is measured in willingness to pay; all money estimates are in 2007/2008
Canadian dollarsthe base case analysis. The AGH subsequent to karyotyping
strategy resulted in a statistically signiﬁcant cost increase
of $110 (95% CI $73–$143) and a nonstatistically signiﬁ-
cant decrease in effectiveness. Employing AGH subsequent
to karyotyping is unlikely to provide good value for money
compared to the baseline AGH strategy and only reaches
a 20% probability of being cost effective when l ¼The Ame$50,000; it never reaches a 95% probability of cost effec-
tiveness.
Sensitivity analysis 3 examined an AGH testing strategy
solely for those individuals without suspected trisomy. The
AGH strategy in this scenario resulted in a statistically
signiﬁcant cost increase of $233 (95%CI $183–$281); AGH
also resulted in 0.091 (95% CI 0.048–0.132) additionalrican Journal of Human Genetics 86, 765–772, May 14, 2010 769
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Figure 2. Cost-Effectiveness Acceptability Curve of Maximum
Willingness to Pay for an AGH Testing Strategy versus a Conven-
tional Testing Strategydiagnoses. The ICER was $2766 (95% CI $1543–$5267)
and there was a 95% probability AGH is cost effective if
l ¼ 4500. The beneﬁt and net beneﬁt of this AGH strategy
was $1117 (95% CI $423–$1984) and $884 ($179–$1757),
respectively. The AGH strategy remains cost beneﬁcial
when those with suspected trisomy are excluded from
the analysis.
In summary, we used decision modeling to examine
whether an AGH strategy in comparison to a conventional
strategy for detecting chromosomal imbalance causing ID
provides good value for money. The AGH strategy resulted
in a statistically signiﬁcant increase in costs, clinical effec-
tiveness, and beneﬁt within the ﬁrst year after a child
undergoes genetic evaluation for ID. In the context of
the commonly cited WTP threshold of $50,000 (i.e., l ¼
50,000) for an effectiveness gain,29 the baseline ICER of
$2646 (95% CI $1619–$5296) per additional diagnosis
suggests that the AGH strategy offers good value for
money. Probabilistic sensitivity analysis revealed that there
is a 95% probability that AGH is cost effective when l ¼
$4550, which is below the $50,000 threshold. However,
we do not know l and, therefore, we used preferences of
families with children who have ID to establish WTP.
The model predicted that the WTP for an additional diag-
nosis was $12,792 (95% CI $6,508–$19,207). At this
threshold, the probability that AGH is cost effective is
more than 99%. The net beneﬁt statistic was $836 (95%
CI $203–$1616). The ICER and net beneﬁt statistics there-
fore suggest that an AGH testing strategy is expected to be
cost beneﬁcial and will provide good value for money
assuming a time horizon of 1 year.
The sensitivity analyses examined how the ICER and net
beneﬁt statistics differed across critical model assumptions.
The conclusion that AGH is cost beneﬁcial did not change
in our sensitivity analyses. Our results suggest that AGH
testing after a karyotype for each individual versus the
use of AGH as ﬁrst-line diagnostic test deﬁned in the base-
line analysis resulted in costs that exceeded beneﬁts overall
because AGH after a karyotype increases average costs by770 The American Journal of Human Genetics 86, 765–772, May 14,$110 (95% CI $73–$143) per patient without signiﬁcantly
changing effectiveness. The use of AGH after an initial
karyotype on all individuals cannot be recommended ac-
cording to our analysis.
This economic evaluation was conducted according to
current methodological guidelines,28 but there are
a number of caveats. First, the cost of the AGH test is likely
to decrease as the technology becomes widely adopted. In
the case of British Columbia, the cost of AGH will decrease
if AGH is covered under the MSP program. This will serve
to improve the cost-beneﬁt of AGH and our analysis is
therefore conservative with respect to this assumption.
Second, effectiveness was not measured by using the
quality adjusted life years (QALY) metric, which is
currently recommended to inform resource allocation
decisions (National Institute for Health and Clinical Excel-
lence). The QALY was not used because of methodological
concerns surrounding the use of preference-based quality
of life measurements in children.30 It may be feasible,
however, to measure the QALY for parents whose children
do or do not have a diagnosis for their ID, which remains
a future avenue for research.
The third caveat is that there are a number of whole-
genome array platforms available to diagnose ID. We
used the term ‘‘AGH’’ in the generic sense to encompass
the class of array technologies that detect submicroscopic
copy number variants. Our analysis does not address the
cost-beneﬁt of any speciﬁc array platform. Fourthly, given
our short-term time horizon, we excluded future economic
costs and beneﬁts associated with a diagnosis or lack of
a diagnosis of ID. This includes the costs and beneﬁts asso-
ciated with more accurate genetic counseling. It is uncer-
tain what effect these omissions will have on the ICER.
Research that projects costs and effects over a longer time
horizon is warranted.
The ﬁfth caveat is related to the chart review and our
inclusion criteria of children between the ages of 5 and
10. This age range was desirable because these children
are more likely to have gone through the full array of labo-
ratory and other testing associated with their ID, but was
limited because children dying before the age of 5 were
excluded from the analysis. Although this limitation is
unlikely to affect the ICER, it may have implications for
the mean cost per patient and the sampling uncertainty
surrounding the cost estimates.
Finally, when an economic evaluation uses an interme-
diate outcome such as the additional number of genetic
diagnoses, statements regarding cost effectiveness require
the assumption of a particular range ofWTP for a diagnosis
among decisionmakers. In our analysis, this was addressed
via the CEAC; any statement wemade regarding cost effec-
tiveness was thus limited to conclusions surrounding the
CEAC. We instead made statements regarding cost-beneﬁt
and value for money, which are broader in scope because
they enable resource allocation decisions to be made
both within health care and across all sectors of the
economy.122010
In conclusion, our analysis suggests that AGH testing for
ID provides good value for money when compared to
conventional karyotyping followed by FISH. Our decision
models also suggest that obtaining a karyotype on all chil-
dren with ID and then testing with AGH if the cytogenetic
analysis does not provide a diagnosis is not cost beneﬁcial
when compared to using AGH as ﬁrst-line diagnostic
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